We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
- Authors
Mounier, Nicolas; Anthony, Sabine; Busson, Raphaël; Thieblemont, Catherine; Ribrag, Vincent; Tilly, Hervé; Haioun, Corinne; Casasnovas, René‐Olivier; Morschhauser, Franck; Feugier, Pierre; Delarue, Richard; Ysebaert, Loic; Sebban, Catherine; Broussais‐Guillaumot, Florence; Damaj, Gandhi; Nerich, Virginie; Jais, Jean‐Philippe; Laborde, Lilian; Salles, Gilles; Henry‐Amar, Michel
- Abstract
<bold>Background: </bold>Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long-term fatigue levels was investigated in a cross-sectional study.<bold>Methods: </bold>Two self-administered questionnaires, the 20-item Multidimensional Fatigue Inventory (MFI-20) and a Life Situation Questionnaire, were mailed in 2015 to NHL survivors enrolled onto 12 successive clinical studies (1993-2010) conducted by the Lymphoma Study Association. Private addresses were obtained for 3317 survivors, of whom 1671 (50%) returned the questionnaires. Severe fatigue was defined as MFI-20 scores ≥60 on dimension scales scored from 0 to 100. Linear regression models were used to assess factors that were linked to increased fatigue levels.<bold>Results: </bold>The study population included 906 men and 765 women, and the median age was 64 years (age range, 24-95 years). Overall, 811 survivors had received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like chemotherapy, 518 had received high-dose CHOP, and 342 had undergone upfront autologous stem cell transplantation; 829 survivors also had received rituximab. In total, 1100 survivors (66%) reported 1 or more late health disorders. Severe fatigue was reported by 602 survivors (37%). Increased fatigue levels were associated (P < .001) with increased age, obesity, and the presence of health disorders, but not with initial treatment or rituximab.<bold>Conclusions: </bold>The survey confirms that high proportions long-term NHL survivors have severe fatigue. The results suggest that initial treatment and the receipt of rituximab have no influence on the development of long-term fatigue.
- Subjects
FATIGUE (Physiology); STEM cell transplantation; CROSS-sectional method; LYMPHOMAS; THERAPEUTICS
- Publication
Cancer (0008543X), 2019, Vol 125, Issue 13, p2291
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.32040